Table2.
Clinical features of subjects
| Characteristic | Correlation with mean PFS-16 (p value/ρ) | |
|---|---|---|
| Number of patients | 56 | — |
| Age; mean±SD (range, years) | 72.5±7.45 (55–92) | 0.029/0.29 |
| Male/female | 25/31 | — |
| Duration; mean±SD (range, years) | 6.39±4.90 (1–23) | 0.128/ |
| Levodopa equivalent daily dose mean±SD (mg) | 406.32±229.39 | 0.392/ |
| Initial H&Y stage; (median: mean±SD) | 3: 3.09±0.91 | 0.043/0.27 |
| Follow-up H&Y stage; (median: mean±SD) | 4: 3.77±1.01 | p<0.001/0.45 |
| Follow-up period; mean±SD (range, month) | 26.71±10.67 (2– –34) | 0.083/ |
| H&Y aggravation during follow-up period; mean±SD | 0.67±0.70 | 0.019/0.31 |
| Mean PFS-16 score, mean±SD | 3.32±0.99 | — |
a) SD: standard deviation. H&Y: Hoehn and Yahr. PFS-16: The 16-item Parkinson Fatigue Scale. ρ: Spearman’s rank correlation coefficient.